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ABSTRACT
Respiratory syncytial virus (RSV) was first 
described 160 years ago but was not officially 
recognized as a cause of serious illness in children 
until the late 1950s. It has been estimated that 
virtually all children have had at least one 
RSV infection by their second birthday. RSV is 
responsible for annual disease outbreaks, usually 
during a defined winter seasonal period that can 
vary by community and year. RSV is recognized 
as the leading cause of hospitalization among 
young children worldwide. Infants of young 
chronologic age and children with predisposing 
factors, such as premature birth, pulmonary 
disease, or congenital heart disease, are most 
susceptible to serious illness. Unlike other 
viruses, immunity to RSV infection is incomplete 
and short lived, and reinfection is common 
throughout life. Initial attempts to develop a 
vaccine in the 1960s met with unexpected and 
tragic results; many children vaccinated with a 
formalin-inactivated wild-type virus developed 
serious pulmonary disease upon subsequent 
natural infection. Numerous other vaccine 
technologies have since been studied, including 
vectored approaches, virus-like particles, DNA 
vaccines, and live attenuated virus vaccine. As of 
early 2010, only two companies or institutions 
had RSV vaccine candidates in early clinical 
trials, and no vaccine is likely to be licensed for 
marketing in the immediate future.
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INTRODUCTION
Respiratory syncytial virus (RSV) is the leading 
cause of serious lower respiratory tract disease 
requiring hospitalization of infants and children 
in the United States1-6 where it accounts for up 
to 120,000 hospitalizations annually in infants 
<12 months of age.4,7,8 On a broader scale, 
RSV is the most common cause of childhood 
acute lower respiratory tract infection.9 Costs 
associated with RSV-related hospitalization 
and outpatient visits for bronchiolitis are on 
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the rise.10,11 The unique ability of RSV to evade 
maternal antibodies and infect infants very early 
in life increases the clinical impact of disease, 
due in part to narrow airways in infants that 
are susceptible to obstruction and an immature 
immune system in these children. In some cases, 
the clinical consequences of RSV-related illness 
do not end in childhood. Long-term studies of 
children hospitalized with RSV-related lower 
respiratory tract illness before age 24 months 
who were prospectively followed up for periods 
ranging from 18 to 25 years indicate that 
severe illness in early life is an independent risk 
factor for wheezing throughout childhood.12-14
Despite the seriousness of RSV illness and its 
complications, there were few accounts of its 
existence as a major viral pathogen before 
the 1950s.
DISCOVERY OF RSV AS A 
RESPIRATORY PATHOGEN
The initial description of infants with cough, 
wheezing, and respiratory difficulty resembling 
asthma 160 years ago is believed to be the first 
report of disease resembling RSV in young 
children (Table 1).15-49 Almost 100 years later, a 
series of winter epidemics was described in which 
a severe viral infection associated with cough, 
dyspnea, fever, bronchiolitis, and pneumonia 
occurred in newborn infants.16,17 In October 
1955, Blount and colleagues at the Walter Reed 
Army Institute of Research (WRAIR) noted 
that several chimpanzees housed for research 
purposes developed a copious nasal discharge 
and sneezing.18 They named the virus that they 
cultured from the nasal secretions “chimpanzee 
coryza agent” (CCA) and were successful in 
inducing the same illness in nonimmune 
animals. A laboratory worker at WRAIR 
coincidently developed similar cold symptoms 
and CCA antibody titers. A year later, Chanock 
and associates recovered a CCA-like virus in 
an infant with bronchiolitis and in another 
infant with pneumonia.19,20 Laboratory studies 
indicated that this virus was indistinguishable 
from the one isolated in the original report by 
Blount et al.18 Sera from a group of infants who 
developed viral lower respiratory tract infections 
over a 5-month period was subsequently 
evaluated and indicated that many of the 
children developed humoral immunity to the 
CCA-like viruses. Chanock was able to show 
that infected cells consisted of multinucleated 
giant cells circumscribed by large syncytia, 
and proposed “respiratory syncytial virus” as a 
more suitable name than CCA for this virus. 
He is credited with the identification of much 
of the early knowledge about the importance 
as RSV as a viral pathogen, as well as with the 
discovery and testing of the RSV formalin-
inactivated vaccine.
A number of reports soon surfaced about 
this newly identified virus and resultant illness 
in children. Beem and colleagues reviewed 
the characteristics of acute respiratory disease 
noted in 41 children infected with the CCA/
RSV virus during the winter of 1958-1959 in 
Chicago.50 The most frequently observed clinical 
diagnoses were bronchiolitis, pneumonia, 
and acute respiratory illness; two deaths were 
noted in patients who tested positive for the 
virus. Isolation of RSV from patients occurred 
between the months of December and April and 
was detected with highest frequency in January 
and February. Prospective studies conducted by 
Chanock’s group during the 1959-1960 winter 
season in Washington, DC, provided further 
evidence of RSV as a significant cause of lower 
respiratory illness in young children.51,52 RSV 
was recovered from 57% of young infants with 
bronchiolitis or pneumonia during a 5-month 
period. Serious illness was most likely during the 
initial infection, especially if it occurred early in 
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Table 1. History of respiratory syncytial virus (RSV) and immunoprophylaxis milestones.
Date Key event
First author, year, 
reference
1850 First clinical description of an illness in children that resembles what is now 
termed respiratory syncytial virus disease.
Eberle 185015
January-March 1937,  
and winter of 1940-1941
Description of two epidemics of bronchiolitis and pneumonia in infants in 





Isolation of a virus, termed CCA, from previously healthy chimpanzees 
housed at Walter Reed Army Institute of Research.
Illness reported in a laboratory worker who was working with CCA and who 
had contact with infected chimpanzees.
Blount 195618
1956 Recovery of CCA-like virus in infants with bronchiolitis and pneumonia; 










1971 Cotton rat shown to be a suitable animal model for study of RSV illness. Dreizin 197125
Late 1970s, early 1980s Additional studies validate cotton rat model of RSV illness. Prince 197826
Prince 198327
1982 Live attenuated RSV vaccine safe but not effective for prevention of 
RSV illness.
Belshe 198228
1983 “Baby Moose”, Native American infant thought to have B streptococcal 
disease but who actually was infected with RSV, serendipitously improved 
when he received IGIV, which prompted study of IGIV for RSV disease.
Mid 1980s-1990 Studies of standard IGIV for treatment and prevention of RSV illness 




Early 1990s Reinitiation of RSV vaccine studies with various subunit varieties. 








Early-mid 1990s Studies of RSV-enriched IGIV for prevention of RSV illness/hospitalization. Groothuis 199339
PREVENT199740
Simoes 199841
(continued on next page)
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life, and subsequent infections were common 
but were usually less severe in the majority of 
children. Outbreaks of additional cases of RSV 
illness were soon identified in communities and 
hospitals between 1959 and 1961 in other parts 
of the United States and around the world.53-57 
Chanock eloquently summarized the state 
of knowledge regarding RSV through 1961, 
and highlighted four key findings that are 
presently considered hallmarks of the virus and 
resultant illness: (1) RSV is a prominent cause 
of bronchiolitis and pneumonia in the young; 
(2) epidemics appear annually each winter for 
a period of 3-5 months but those months vary 
from year to year; (3) most children become 
infected by age 4 years; and, (4) reinfection can 
Table 1. History of respiratory syncytial virus (RSV) and immunoprophylaxis milestones. (Continued)
Date Key event
First author, year, 
reference
January 1996 Licensure of RespiGam for prevention of serious lower respiratory 
tract infection caused by RSV in children younger than 24 months 
with bronchopulmonary dysplasia (now termed chronic lung disease of 
prematurity) or a history of premature birth.
Mid 1990s Initiation of clinical trials with three distinct monoclonal antibodies 
(MEDI-493/palivizumab, HNK20, and RSHZ19/SB209763) for 





Mid 1990s Failure of RSV-IGIV treatment of RSV in high-risk hospitalized children. Rodriguez 199745
1995-1996 RSV season Positive clinical trial of palivizumab for prevention of serious lower 
respiratory tract disease caused by RSV in infants with CLD and infants 
with a history of premature birth (≤35 weeks GA).
IMpact-RSV Study 
Group 199842
June 1998 Licensure of palivizumab/Synagis for prevention of serious lower respiratory 
tract disease caused by RSV in infants with CLD and infants with a history of 
premature birth (≤35 weeks GA).
1998-2002 RSV seasons Positive clinical trial of palivizumab for prevention of serious lower 
respiratory tract disease caused by RSV in infants with hemodynamically 
significant CHD.
Feltes 200346
September 2003 Licensure of palivizumab/Synagis for prevention of serious lower respiratory 
tract disease caused by RSV in infants with hemodynamically significant 
CHD.
Mid-late 2000s Initiation of clinical trials with motavizumab for prevention of serious lower 





Early-mid 2000s Initiation of live attenuated RSV vaccine trials.
Late 2000s Initiation of Sendai virus RSV vaccine trials.
CCA=chimpanzee coryza agent; CHD=congenital heart disease; CLD=chronic lung disease of prematurity; 
GA=gestational age; IGIV=immune globulin intravenous; RSV-IGIV=RSV immune globulin intravenous (RespiGam).
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occur, but is generally associated with a milder 
form of illness.58 These early observations paved 
the way for further study into the epidemiology 
and prevention of RSV disease.
EPIDEMIOLOGY AND RISK 
FACTORS FOR SERIOUS ILLNESS
One of the unusual features of RSV is the 
high frequency of childhood reinfection; 
initial infection does not protect against 
subsequent infection, even with the same 
strain of virus.59-62 Henderson et al. conducted 
a 10-year prospective study to examine the 
characteristics of reinfection with RSV in 
infants and young children who attended a 
research daycare program.62 Repeat infections 
were associated with less severe disease than the 
initial occurrence, and an inverse relationship 
was observed between age and lower respiratory 
tract involvement. The investigators concluded 
that future efforts at immunoprophylaxis would 
likely result in a reduction in the severity of 
disease rather than prevention of infection. 
Researchers in Houston conducted a longitudinal 
study of RSV infection in 125 children followed 
up from birth to 60 months of age from 1975 to 
1980 to quantify the risk of primary infection 
and reinfection with RSV.60 Approximately two-
thirds (68%) of children experienced their initial 
infection before their first birthday, and nearly 
all were infected at least once by 24 months of 
age. Lower respiratory involvement occurred 
less often in children who experienced their 
primary infection after 12 months of age than in 
their younger counterparts (5.9% versus 21.6%, 
respectively). Reinfection was common (75.9% 
in year 2, 45.3% in year 3) and declined with age. 
It was associated with milder disease and was 
inversely related to the level of the pre-existing 
neutralizing antibody titer and number of prior 
infections. A similar correlation between the 
level of neutralizing antibodies and RSV disease 
severity has been reported by others.59,63-67
Researchers have identified several medical 
conditions and associated risk factors that 
predispose children to severe RSV disease and 
subsequent hospitalization.68,69 Preterm births, 
which have increased more than 20% since 1990, 
form the largest high-risk special population 
for severe RSV infection. The largest growth 
segment within this group consists of the late-
preterm infant born between 34 and 36 weeks 
gestational age (GA).70 Late-preterm infants, who 
now account for more than 70% of all premature 
births, experience greater morbidity and 
mortality and more frequent rehospitalization 
after initial discharge and throughout the first 
year of life than term infants.71 These children 
are especially prone to high rates of respiratory 
disorders, including RSV infection.72-75
Children with chronic lung disease 
of prematurity (CLD; formerly known as 
bronchopulmonary dysplasia [BPD]) and 
hemodynamically significant congenital heart 
disease (CHD) are among those at highest risk 
for severe RSV illness. Up to 30% of infants born 
with CLD will eventually be hospitalized with 
an RSV-related infection during their first 2 years 
of life.72,76 Similar hospitalization rates have also 
been reported for those with CHD.77 Children 
with CLD or CHD incur longer RSV-related 
hospital stays, have greater need for intensive 
care unit resources, and have higher mortality 
rates than other high-risk children.77,78 Other 
medical conditions that have been reported 
to predispose children to serious RSV disease 
include severe neuromuscular disease, congenital 
abnormalities of the airways, cystic fibrosis, and 
severe immunodeficiencies.69,79,80
A plethora of literature has described nearly 
two dozen risk factors (social, demographic, 
and environmental) for severe RSV-related 
disease and/or bronchiolitis. Age of an infant 
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at the onset of the RSV season is one of the 
most important and universally agreed on risk 
factors for serious RSV illness. Some investigators 
have found greater risk associated with age 
<3 months,81,82 but others have found the risk 
to be associated with infants aged <6 months.3,83
Additional risk factors include young siblings 
in the household,81,82,84 daycare attendance,82,84
exposure to environmental tobacco smoke,81,82,85
low birth weight,86 family history of wheezing 
or asthma,82,84 certain neuromuscular diseases, 
immunosuppressed states,87 and multiple 
births.87,89 The significance of these risk factors is 
periodically reviewed by the American Academy 
of Pediatrics along with recommendations on 
immunoprophylaxis in select at-risk groups 
of children.69
THE ROLE OF INFLAMMATORY 
RESPONSES IN DISEASE 
PATHOGENESIS
The relative contribution of host versus viral 
factors to the pathogenesis of RSV disease remains 
controversial and incompletely understood. RSV 
is highly contagious but is not highly cytopathic 
or invasive. However, the tropism of RSV for 
the superficial epithelial cells of the respiratory 
tract reduces the effectiveness of host immunity. 
Further, the ability of RSV to infect so early in 
life causes more frequent and severe disease than 
most other respiratory viruses. This is due in part 
to the small size and the narrower and immature 
airways of the young infant. Further protective 
immune responses in young infants are neither 
complete nor long lasting. Commonly proposed 
immunologic features include exaggerated 
cytotoxic T-lymphocyte responses, imbalanced 
T-helper cell (Th)2/Th1 responses, and 
exaggerated inflammatory responses, coupled 
with insufficient or altered responses due to 
young age or as yet unexplained viral factors. 
Exaggerated inflammatory responses may lead 
to upregulation in the expression of chemokines 
and the further activation of nuclear factor 
kappa B. This in turn leads to the production of 
inflammatory factors such as neutrophils, which 
can contribute to tissue damage, and other effects 
such as hyper-reactivity. Genetic predisposition 
to severe RSV infection, prematurity, and/or 
pulmonary, cardiac, and immunologic 
compromise may also play an important role in 
disease severity. A better understanding of the 
viral and host determinants of immunologic 
responses to RSV will be important for designing 
vaccines and other preventative agents in 
the future.90
MATERNAL IMMUNOGLOBULIN G 
AND ROLE OF RSV-SPECIFIC 
MATERNAL ANTIBODIES IN RSV 
DISEASE
Maternal immunoglobulin G (IgG) is not 
efficiently transferred to the fetus until the third 
trimester of pregnancy, and a linear relationship 
has been established between the logarithm 
of the serum IgG levels and GA. Yeung et al. 
evaluated serum IgG levels of premature and 
term infants and showed that mean serum 
concentrations ranged from 180 to 656 mg/dL 
in infants born at 24.5 to 35.5 weeks GA, to 757 
to 1100 mg/dL in infants born at 37 to 40 weeks 
GA.91 A high proportion of premature infants 
remain hypogammaglobulinemic at 6 months of 
age.92 Brandenburg and associates measured the 
decline in maternal RSV-specific antibodies over 
a 6-month period in 45 healthy term infants.93
Antibodies were detected in all infants at birth 
(geometric mean titer [GMT], 301), steadily 
declined over the first 3 months (GMT, 24), and 
were undetectable in the majority of infants at 
age 6 months. The calculated mean half-life of 
the antibodies was 26 days. Hacimustafaoglu 
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et al. studied the decline in maternal RSV 
antibodies in the offspring (84% full term, 10% 
GA of 35-38 weeks, 6% GA of 32-35 weeks) 
of 49 pregnant women, 83% of whom tested 
positive for anti-RSV IgG.94 At birth, maternal 
antibodies for RSV were detected in all offspring 
of RSV antibody-positive women and in similar 
concentrations. Antibody levels declined steadily 
over the 6-month observation period and were 
measurable in 73%, 6%, and 2% of infants at 1, 
3, and 6 months, respectively.
Ogilvie et al. prospectively studied 100 infants 
to determine the role of maternal RSV antibodies 
on the development of subsequent disease 
during the first 6 months of life.66 Infants who 
did not become infected with RSV had higher 
mean titers of IgG than infected infants and were 
born to mothers who had significantly higher 
maternal RSV-specific IgG antibody levels than 
the mothers of infants who became infected. 
Ochola and coworkers characterized the levels 
of RSV maternal antibodies and their decay 
rate in 635 newly delivered babies in a rural 
area of Kenya.95 Nearly all children (97%) had 
detectable levels of maternal RSV IgG at birth; 
levels that declined rapidly thereafter. Infants 
who subsequently experienced an infection in 
the first 6 months of life had lower cord titers 
of anti-RSV antibody than the infants who 
did not.
The role of maternal antibody on the 
severity of RSV disease was studied in 15 infants 
with pneumonia (mean age, 4.9 months) 
and 19 infants with bronchiolitis (mean age, 
4.2 months), all of whom were <9 months of 
age at the time of admission to hospital.65 The 
composite GMT in eight children with RSV 
illness aged 1 to 2 months (four each with 
pneumonia and bronchiolitis) was 41, and 
steadily declined to a level of 10 in four children 
aged 3 to 4 months with bronchiolitis, and to 
<8 in 15 children (seven with pneumonia, eight 
with bronchiolitis) aged 5 to 6 months. Titers 
of neutralizing antibody were undetectable 
in the remaining hospitalized children aged 7 
to 8 months. In the small sample of infants 
with pneumonia, linear regression of clinical 
illness scores on the level of neutralizing 
antibody showed a significant (P<0.02) inverse 
correlation between the severity of illness and 
antibody concentrations. No such relationship 
was observed for bronchiolitis. It was later 
demonstrated that antibody to the fusion protein 
is an important correlate of immunity and 
that children with less severe RSV disease have 
significantly higher IgG and anti-F titers before 
infection than children with lower respiratory 
tract involvement.64 The results of these studies 
suggest that maternal RSV IgG antibodies offer 
protection from severe illness in term infants 
during the first few months of life and help 
explain why premature infants are at high risk 
of serious illness.
HISTORY OF RSV VACCINE 
DEVELOPMENT
The history of the initial efforts to develop an 
RSV vaccine began shortly after RSV was first 
isolated. In 1961, the National Institute for 
Allergy and Infectious Diseases considered RSV 
disease a research priority and sponsored the 
first vaccine trials. Earlier research with formalin 
as an inactivation agent led to the development 
of clinically effective vaccines, such as the 
inactivated polio vaccine, so a similar approach 
was used to develop a formalin-inactivated (FI) 
vaccine against RSV. The vaccine was prepared 
in the department of biologics research at Pfizer 
from a Bernett strain isolated in 1961 at the 
US National Institutes of Health (NIH) from 
a volunteer previously inoculated with RSV 
virus.24 The virus was grown in vervet monkey 
kidney tissue cultures, passaged three additional 
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Table 2. Formalin-inactivated respiratory syncytial virus (RSV) vaccine studies.





Primarily black low 
socioeconomic class children 
2-7 months of age.
260 children received 
1 dose between December 
1965 and December 1966.
125 children received 
three doses (weeks 0, 4, 12).
80% of vaccinees required 
hospitalization with more 
severe disease at time of 
RSV infection versus 5% for 
controls. Two children died.
Predominant signs of 




Highest incidence of serious 





Otherwise normal homeless 
children aged 6 months to 
approximately 4.5 years who 
resided in a welfare  
institution.
146 children received 
three doses (weeks 0, 4, 
8), with first dose given 
February 1966 and last 
dose given December 1966.
Exaggerated and altered 
clinical response to infection 
was noted.
69% (9/13) of vaccinated 
children aged 6-23 months 
developed pneumonia versus 
9% (4/47) of controls.
Kapikian 
196923
Fort Ord, CA, 
USA
Children of army personnel 
divided into two groups:  
children aged 4 months to 
9 years; preschool attendees 
through 9 years of age.
191 children received 
two doses (weeks 0, 4), 
and 28 received one dose.
Immunization began 
September 1966, and last 
dose was given December 
1966.
Significantly more vaccine 
recipients were admitted to 
the hospital, and had more 




Children of military personnel 
at Lowry Air Force Base or 
Fitzsimmons Hospital between 
the ages of 6 months to 7 years.
464 children received 
three doses (weeks 0, 4, 8) 
beginning in July 1966.
Significantly higher rate for 
RSV hospitalization (2.4% 
versus 0.1% to 0.37%) in 
vaccinated group versus 
controls.
Age-related incidence 
of hospitalization in 
vaccinated group: infants 
aged 6-11 months, 13.7%; 
children aged 12-36 months, 
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times in primary human embryonic kidney 
cultures and 10 more times in vervet monkey 
kidney cultures. A dilution of the seed virus 
was inoculated into vervet monkey kidney 
bottle cultures, and resultant tissue culture fluid 
harvests were inactivated with formalin. Fluids 
were centrifuged and the pellet residues were 
further concentrated through two additional 
procedures including one involving precipitation 
with alum. Preservatives were added, and the 
final product, which was concentrated 100 times, 
became widely known as Lot 100.
A series of four field efficacy trials were 
initiated in December 1965 and conducted 
through the 1966-1967 RSV season under 
sponsorship of the NIH (Table 2). Lot 100 
was administered in a series of up to three 
intramuscular injections usually 1 month apart 
to approximately 1200 children aged 2 months 
to 9 years. The control groups consisted of either 
nonvaccinated children or children vaccinated 
with a FI-parainfluenza vaccine. The FI-RSV 
vaccine proved to be highly immunogenic and 
elicited high titers of RSV antibody, but the 
antibodies were later shown to be devoid of 
neutralizing and fusion-inhibiting activity.96-98 
Infants aged 2-6 months had high F glycoprotein 
antibody titers but had low G glycoprotein 
antibody titers.97 Children aged 7-40 months had 
F and G antibody titers comparable with those 
found in children who were infected with RSV. 
Both groups of children developed a lower level 
of neutralizing antibodies than did individuals 
of comparable age with natural RSV infection.
During the RSV season, significantly more 
RSV vaccinees were hospitalized with severe, 
enhanced pulmonary disease upon infection 
with wild-type virus. In one of the field studies, 
the hospitalization rate was approximately 80% 
compared with 5% for RSV unvaccinated controls: 
two infants who were initially immunized 
at 5 months or younger subsequently died.24 
Disease experienced in hospitalized children 
given Lot 100 usually consisted of pneumonia 
and/or bronchiolitis and hypoxemia, compared 
with milder disease (rhinitis, pharyngitis, and/or 
bronchitis) in control children <6 months of age, 
a group in whom maternal antibody is normally 
present. The FI-RSV vaccine appeared to stimulate 
an unbalanced immune response in which a 
large proportion of the induced antibodies were 
directed against nonprotective epitopes in place 
of epitopes that induce functional antibodies.98
Given that enhanced disease occurred most 
often in Lot 100 recipients <6 months of age 
and in those who had significant levels of serum 
antibody when illness occurred, it was concluded 
that serum antibody played a major role in the 
pathogenesis of serious RSV illness. Subsequent 
surveillance studies65-67 and RSV prophylaxis 
trials of RSV-enriched immune globulin39 and 
RSV-specific monoclonal antibodies42 have long 
since proven that the initial antibody hypothesis 
was incorrect. Many theories have emerged since 
the publication of the results of the Lot 100 
studies that offer insight into the potential 
mechanisms for vaccine-enhanced disease. The 
most widely propagated theories suggest that the 
mechanisms responsible for enhanced disease are 
both complex and multifactorial. Among these 
include development of poorly neutralizing 
antibodies, lack of protection due to formalin 
disruption of key epitopes during vaccine 
inactivation, exaggerated/biased Th2 response 
resulting in a strong pulmonary eosinophilic 
response, and lack of affinity maturation due 
to deficient Toll-like receptor activation in B 
cells.99-108 However, despite 40 years of research, 
the precise etiology of vaccine-enhanced disease 
from the failed Lot 100 trials has yet to be 
conclusively elucidated.
The unfortunate and catastrophic results 
from the Lot 100 vaccine trials led to a period 
of inactivity in RSV vaccine research, primarily 
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Table 3. Characteristics of representative vaccine technologies for prevention of respiratory syncytial virus (RSV) illness.
Vaccine technology Characteristics
Alphavirus vector Alphavirus vaccines have shown excellent protection in numerous models for infectious disease and cancer, 
including influenza, CMV, breast cancer, melanoma, SARS, HPV, HSV, RSV, PIV, Marburg and Ebola viruses, viral 
encephalitis viruses, and botulinum toxin.
Safe and highly immunogenic in humans.
Induces broad and robust humoral and cellular immune responses.
Capable of expressing a wide array of bacterial, viral, parasitic, and tumor antigens.
Naturally targets dendritic cells, the most efficient antigen-presenting cell in the body.
Allows combination products to be produced through multigene or particle mixtures.
DNA vaccine Antigen can be expressed without alterations to its original structure, and the vaccine can be made optimally 
attenuated and highly immunogenic.
May be well suited for maternal immunization; protective immunity has been demonstrated in mice when maternal 
antibodies were present.
Initial studies have suggested that DNA vaccines are immunogenic but offer only mildly protective effects in RSV 
challenge studies.
Large amounts of DNA are required, although methods to overcome this include novel formulations such as 
nanoencapsulation and microparticles.
Other proposed concerns include the risk of inducing autoimmune responses and tolerance to the administered antigen.
Live attenuated virus Can be administered intranasally and induce a balanced local and systemic immune response.
Potential efficacy in infants with maternal antibodies.
Problems may arise concerning over/underattenuation.
Must be frozen.
SeV vector Well tolerated in preclinical and phase 1 studies.
SeV does not infect humans (naturally attenuated).
SeV confers Jennerian protection against hPIV-1.
SeV and rSeV induce rapid (by day 7) and long-lasting antibody responses versus hPIV-1 and passenger gene targets.
rSeV-RSV-F produces RSV-specific antibody and T-cell responses and protects against RSV  
A and B subtypes.
Can be formulated for intranasal administration.
The virus is easy to grow and can be manufactured in large lots.
VSV vector VSV has been shown to be an effective vaccine vector for use as immunoprophylaxis against numerous viral 
infections and to induce an immune response against cancer. The following diseases have been studied: hepatitis C, 
HIV, influenza, HPV, Ebola, RSV.
VSV is not a human pathogen, and there is little pre-existing immunity that might impede its use in humans.
It propagates efficiently in cell lines suitable for manufacturing immunogenic compositions.
VSV infection is an efficient inducer of both cellular and humoral immunity.
It can be administered intranasally or parenterally.
VLPs VLP technology serves as the platform used by Merck and GlaxoSmithKline for marketed vaccines for HPV 
(ie, Gardisil, Cervarix) and hepatitis B (ie, Recombivax HB, Engerix B), and is currently being used in the 
development of vaccines for a number of infectious diseases (eg, influenza, norovirus, HIV, herpes zoster, RSV).
Potent humoral immune response for protection against RSV disease.
Cell-mediated immune response for clearance of RSV infection.
Th1-weighted response.
No replication should result in limited reactogenicity.
Unlikely to be associated with enhanced disease.
Potential for multiple routes of administration.
Ease of production and manufacturing (does not require eggs).
CMV=cytomegalovirus; HIV=human immunodeficiency virus; hPIV-1=human parainfluenza virus 1; HPV=human papillomavirus; 
HSV=herpes simplex virus; PIV=parainfluenza virus; SARS=severe acute respiratory syndrome; SeV=Sendai virus; VLP=virus-like particle; 
VSV=vesicular stomatitis virus.
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owing to liability concerns faced by researchers 
and drug manufacturers.109 Results of a 
preliminary trial of a live RSV vaccine in the 
early 1980s revealed that the vaccine was not 
effective in the children studied.28 Further trials 
were initiated in the 1990s with several subunit 
RSV vaccines composed of either purified F 
glycoprotein (PFP-1, PFP-2, PFP-3) or BBG2Na, a 
peptide from the G glycoprotein.32-36,38 The vaccine 
population consisted of children >12 months 
of age, young adults, institutionalized and 
older adults, and pregnant women. There were 
some hypersensitivity reactions to the BBG2Na 
formulation; nevertheless, the vaccines were 
capable of inducing neutralizing antibodies. 
However, the observed reduction in incidence 
of RSV-related lower respiratory tract illness in 
late-phase studies was not sufficient to warrant 
further investigation in children younger than 
12 months and blunted further interest in 
additional research with subunit vaccines for 
RSV prevention.
Numerous other vaccine technologies 
have since been studied, including vectored 
approaches (eg, Sendai virus, alpha virus, 
vesicular stomatitis virus, modified vaccinia 
Ankara, adenovirus), virus-like particles, 
DNA vaccines, and live attenuated virus 
vaccines.110-113 Each has its own advantages and 
disadvantages (Table 3). As of early 2010, only 
two companies or institutions had RSV vaccine 
candidates in the clinic (live attenuated and 
Sendai virus vector), and no vaccine is likely to 
be licensed for marketing for at least 8 years. 
Maternal immunization with an RSV vaccine 
has been proposed as an alternative to infant 
immunization. However, this would not be 
effective for most premature infants because 
maternal IgG is not transferred efficiently 
until the third trimester of pregnancy. In 
addition, the safety of such an approach 
remains uncertain.
There are many challenges to overcome 
before a successful RSV vaccine can be licensed 
for administration in very young infants.109,111,114
The most daunting hurdle is that to prevent 
clinically significant illness and reinfection, the 
vaccine would have to confer greater immunity 
than that which occurs from natural infection 
with wild-type virus. A better understanding of 
the immune response to RSV infection is clearly 
necessary to further vaccine research.115 The 
primary targets for RSV vaccination are neonates 
and young infants. They have immature 
immune systems and may not be able to elicit a 
robust immune response following vaccination 
in the presence of maternally acquired antibody. 
Strategies traditionally employed to overcome 
this problem involve the administration of more 
than one vaccine dose and delay in vaccination 
until after 6 months of age. Neither of these 
approaches is ideal. In addition, the RSV vaccine 
must not interfere with the safety and efficacy 
of other routine childhood vaccines. Assuming 
all of these obstacles can be overcome, given 
the history of Lot 100, regulatory bodies may 
question the safety and efficacy of vaccine 
candidates for prevention of RSV disease 
especially if the technology chosen has not been 
previously validated in young children or if a 
maternal immunization strategy is considered.
EXPERIMENTAL ANIMAL MODELS 
OF RSV INFECTION
Although no safety concerns emerged following 
results of short-term potency and safety tests 
performed on the initial RSV Lot 100 vaccine in 
animals according to standard tests at that time, 
preclinical efficacy studies were not conducted 
because a reputable animal model for RSV had 
not yet been identified. Animal models of RSV 
infection that have been studied include the 
ferret, cotton rat, primates (eg, chimpanzee, 
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monkey, baboon), mouse, cow, and pig.116 Of 
these, the ferret and cotton rat have proven to 
be useful and easy-to-study models with RSV 
infection and IgG antibody response in the 
cotton rat most closely mimicking RSV infection 
that occurs in humans.
Ferret
Data from Chanock’s research group in the 
early 1960s in ferrets showed that RSV could 
be cultured from the nose for 1 week and from 
the trachea for 4 days following intranasal 
inoculation.117 However, no significant pathologic 
changes were observed in the pulmonary tree. 
Results from subsequent studies conducted in 
ferrets of various age groups indicated that RSV 
was detected in nasal mucosa and replicated in 
the lungs of infant ferrets, but the latter effects 
disappeared by age 4 weeks.118 Minimal or no 
neutralizing antibody was detected regardless of 
when inoculation occurred (ie, from birth to age 
28 days). These findings indicate that the ferret is 
not an ideal model for study of RSV because they 
are only susceptible to the pulmonary effects of 
disease up to adolescence and do not develop a 
robust antibody response.
Cotton Rat
In a study conducted in Russia, Dreizin et al. 
were the first to demonstrate that RSV replicated 
in high titers throughout the respiratory tract 
of the common cotton rat (Sigmodon hispidus).25
Maximum viral replication occurred on the 
fourth day following inoculation, and disease-
related effects mainly involved the surface 
epithelium in the nose, trachea, and lungs. 
Because findings from this study were published 
in Russian, it took several years before a series 
of additional studies, which were conducted 
by Chanock’s group at the NIH, validated and 
extended Dreizin’s findings and confirmed the 
usefulness of this model.26,27,119 Viral replication 
was shown to be restricted to epithelial 
cells, with high titers noted in the nose and 
lungs.26 Animals exhibited exudative rhinitis 
of moderate severity and mild proliferative 
bronchiolitis, with serum neutralizing antibody 
present in all animals between days 5 and 9 
postinfection that was not influenced by age 
at the time of infection. Cotton rats developed 
complete resistance to pulmonary reinfection, 
which lasted for at least 18 months, whereas 
resistance to infection in the nose was of shorter 
duration and began to diminish at 8 months.27 A 
correlation was observed between resistance and 
serum neutralizing antibody levels.
The quantitative aspects of passive immunity 
to RSV were further studied to determine 
the level of neutralizing antibodies in serum 
required to confer resistance.119 Infant animals 
were inoculated with set dilutions of a single 
pool of sera derived from animals that were 
convalescent from active infection and then 
subjected 24 hours later to intranasal inoculation 
with RSV. A serum neutralizing antibody titer of 
1:100 or greater was associated with suppression 
of virus replication in the respiratory tract with 
complete/almost complete resistance in the 
lungs noted at a serum neutralizing antibody 
titer of ≥1:380. The investigators noted that a 
less striking protective effect of serum antibody 
was observed for nasal tissues, a finding that 
was further explored by Siber and associates a 
decade later.120 Siber’s group evaluated the effects 
of low-dose (0.5 g/kg) and high-dose (5.0 g/kg) 
RSV-enriched immune globulin (IG) and 
conventional IG with respect to their antibody 
concentrations to RSV and protective activity 
against RSV challenge in cotton rats. Serum 
neutralizing antibody activity was determined 
24 hours after intraperitoneal administration 
of each IG and immediately prior to intranasal 
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challenge. Mean neutralizing titers following 
high-dose IG were similar to those produced 
by low-dose RSV-IGIV, whereas titers following 
high-dose RSV-IGIV were significantly higher 
than those after high-dose IG (17,200±1350 MU/
mL by microneutralization versus 3800±393 MU/
mL, respectively; P<0.01). The serum neutralizing 
antibody titer necessary to lower lung virus 
concentration by 99% was determined to be 
1:390, whereas that required to reduce nasal 
virus concentrations by 99% was calculated to 
be 1:3500. Results from this study demonstrated 
that the in vivo protective activity of RSV-IGIV 
was significantly greater than that of IG and 
that RSV-IGIV is approximately 10 times more 
effective in preventing RSV disease in the lower 
airways than in the upper respiratory tract. 
The concentration of serum RSV-neutralizing 
antibodies necessary to provide resistance to 
infection in these early cotton rat studies was 
similar to the level of maternally derived serum 
antibodies present in human infants <2 months 
of age. Both of these findings help explain later 
results obtained during human clinical trials of 
RSV-IGIV and RSV monoclonal antibodies for 
prophylaxis against serious lower respiratory 
tract disease following RSV infection. Results 
from these early studies provided evidence that 
the cotton rat is the best animal model of those 
tested for studying RSV infection and antibody 
response thus far. Limitations of this model 
include the fact that cotton rats do not develop 
measurable clinical disease and cannot, at 
present, be utilized to model cellular immunity.
CONCLUSION
RSV is unique among respiratory viruses in 
that it infects infants at an early age, and those 
affected do not develop sufficient immunity to 
prevent subsequent reinfection. It is the leading 
cause of hospitalization in infants younger 
than 1 year in the United States. There are no 
vaccines currently available for prevention of 
serious RSV illness, and none are likely to be 
licensed in the near future. Immunoprophylactic 
treatment with polyclonal and monoclonal 
antibody preparations against RSV has been 
developed to prevent RSV infection and reduce 
subsequent morbidity. In the second part of 
this series we will discuss the clinical history 
of immunoprophylaxis with antibodies in 
infants and children at high risk for serious 
RSV disease.
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